Clinical Trials Logo

Clinical Trial Summary

The primary objective is to evaluate the impact of afamelanotide on the severity of skin disease in patients with Variegate Porphyria (VP). The secondary objectives are to evaluate the safety and tolerability of afamelanotide in patients with VP and evaluate the impact of afamelanotide on the quality of life of patients with VP.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05854784
Study type Interventional
Source Clinuvel Pharmaceuticals Limited
Contact
Status Completed
Phase Phase 2
Start date March 28, 2023
Completion date December 28, 2023

See also
  Status Clinical Trial Phase
Terminated NCT02922413 - Panhematin for Prevention of Acute Attacks of Porphyria Phase 2
Active, not recruiting NCT02935400 - Acute Porphyria Biomarkers for Disease Activity